Xuan Song

Dr. Xuan Song

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2023 in Clinical Nutrition
Verified
Journal Article
Open access
XLXinyan Liu
Xinyan Liu
QWQizhi Wang
Qizhi Wang
DYDaqiang Yang
Daqiang Yang
MFMaoliang Fu
Maoliang Fu
MYMaopeng Yang
Maopeng Yang
XSXuan Song
Xuan Song
Recently, the Gastrointestinal Dysfunction Score (GIDS) was developed for use with critically ill patients. This study evaluated the association of GIDS with disease severity and clinical outcomes to assess the technical feasibility of using GIDS to reflect the severity and short-term prognosis of critically ill patients. Association between Gastrointestinal Dysfunction Score (GIDS) and disease severity and prognosis in critically ill patients: A prospective, observational study. This was a prospective observational study involving adult patients in two Intensive Care Units (ICUs). During the first seven days of ICU admission, GIDS, acute gastrointestinal injury (AGI), Acute Physiology and Chronic Health Evaluation II (APACHE II), and Sequential Organ Failure Assessment (SOFA) scores were assessed daily. A total of 276 patients from two centers were enrolled in this study. Patients were divided into GIDS 0-1 (121, 43.8%) and GIDS 2-4 (155, 56.2%). The ICU length of stay and 28-day mortality in the GIDS 2-4 group were significantly higher than the GIDS 0-1 group (P = 0.032, P = 0.001, respectively). The APACHE II and SOFA scores in the GIDS 2-4 group were also significantly higher (P < 0.001). The ROC curves of GIDS, AGI, APACHE II, and SOFA scores on the first day of ICU admission for the prediction of 28-day mortality showed that the AUC of GIDS was 0.702 (95%CI 0.628, 0.775; P < 0.001). The AUC for GIDS + SOFA was 0.719 (95%CI 0.648, 0.790; P < 0.001), compared with SOFA alone (AUC = 0.703), showing improved predictive power for 28-day mortality. GIDS represents a step toward a reliable clinical tool for GI dysfunction to assess disease severity and short-term prognosis in critically ill patients. In addition, combining GIDS with SOFA score may better predict mortality risk compared to SOFA score alone.

11 August 2023 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
XLXinyan Liu
Xinyan Liu
EBErin F. Barreto
Erin F. Barreto
YDYue Dong
Yue Dong
CLChang Liu
Chang Liu
XGXiaolan Gao
Xiaolan Gao
Kianoush KashaniKianoush Kashani
Kianoush Kashani
Background: Artificial intelligence (AI) tools are more effective if accepted by clinicians. We developed an AI-based clinical decision support system (CDSS) to facilitate vancomycin dosing. This qualitative study assesses clinicians' perceptions regarding CDSS implementation. Methods: Thirteen semi-structured interviews were conducted with critical care pharmacists, at Mayo Clinic (Rochester, MN), from March through April 2020. Eight clinical cases were discussed with each pharmacist (N = 104). Following initial responses, we revealed the CDSS recommendations to assess participants' reactions and feedback. Interviews were audio-recorded, transcribed, and summarized. Results: The participants reported considerable time and effort invested daily in individualizing vancomycin therapy for hospitalized patients. Most pharmacists agreed that such a CDSS could favorably affect (N = 8, 62%) or enhance (9, 69%) their ability to make vancomycin dosing decisions. In case-based evaluations, pharmacists' empiric doses differed from the CDSS recommendation in most cases (88/104, 85%). Following revealing the CDSS recommendations, we noted 78% (69/88) discrepant doses. In discrepant cases, pharmacists indicated they would not alter their recommendations. The reasons for declining the CDSS recommendation were general distrust of CDSS, lack of dynamic evaluation and in-depth analysis, inability to integrate all clinical data, and lack of a risk index. Conclusion: While pharmacists acknowledged enthusiasm about the advantages of AI-based models to improve drug dosing, they were reluctant to integrate the tool into clinical practice. Additional research is necessary to determine the optimal approach to implementing CDSS at the point of care acceptable to clinicians and effective at improving patient outcomes.

18 October 2021 in Trials
Verified
Journal Article
Open access
PDF file
MYMaopeng Yang
Maopeng Yang
XLXinyan Liu
Xinyan Liu
DYDaqiang Yang
Daqiang Yang
YBYahu Bai
Yahu Bai
BQBingxin Qin
Bingxin Qin
XSXuan Song
Xuan Song
Background: Delirium is an acute cognitive disorder that presents with fluctuation in cognition, apathy, and non-organized thinking, resulting in increased morbidity, mortality, intensive care unit (ICU) stay, and total healthcare costs. In patients undergoing cardiac surgery, delirium also increases the risk of postoperative complications, such as respiratory insufficiency, sternum instability, and need for re-operation of the sternum. This study aims to understand the incidence of delirium in patients after cardiac surgery in patients sedated with remimazolam besylate versus propofol. Methods: In this prospective, double-blind, randomized controlled clinical trial, we aim to recruit 200 patients undergoing cardiac surgery between January 1, 2021, and December 31, 2021, who will be randomized to receive either remimazolam besylate or propofol infusions postoperatively, until they are extubated. The primary outcome is the incidence of delirium within 5 days after surgery. Secondary outcomes include the time of delirium onset, duration of delirium, ICU length of stay, hospital length of stay, and mechanical ventilation time. Discussion: The key objective of this study is to assess whether remimazolam besylate reduces the incidence of delirium in patients after cardiac surgery compared to propofol sedation. In this preliminary randomized controlled clinical trial, we will test the hypothesis that the use of remimazolam besylate lowers the incidence of delirium when compared to propofol in patients undergoing cardiac surgery. Trial registration: chictr.org.cn ChiCTR2000038976. Registered on October 11, 2020

24 January 2023 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
ATAlessandra Tomasi
Alessandra Tomasi
XSXuan Song
Xuan Song
OGOgnjen Gajic
Ognjen Gajic
Kianoush KashaniKianoush Kashani
Kianoush Kashani
Background The relationship between the lung and kidney investigated in animal and clinical models has demonstrated substantial crosstalk. We aimed to evaluate the association between single vs. concurrent AKI and ARDS and its impact on patient outcomes. Secondly, we aimed to assess whether the order of appearance of these pathologies affected patient outcomes in patients with both diseases. Methods This single-center retrospective cohort study included adult patients admitted to the ICU from January 1, 2007 through May 1, 2018 (n = 76,988). Baseline characteristics and outcomes were compared among patients without ARDS or AKI and those with one or both ARDS and AKI. We also assessed outcomes across the order of appearance of these diseases among patients with both AKI and ARDS. Results We enrolled 76,988 unique patients in the final analysis: 47,043 patients with neither AKI nor ARDS, 491 patients with ARDS alone, 27,928 patients with AKI alone, and 1,526 patients with both ARDS and AKI. Patients with both ARDS and AKI had higher ICU (21.2%) and hospital (28.4%) mortality compared to patients with ARDS alone (9.0% ICU mortality, 14.0% hospital mortality) or AKI alone (4.4% ICU mortality, 8.4% hospital mortality) (p < 0.001). These findings remained unchanged after adjusting for illness severity and comorbidities. Of the 1136 patients with both AKI and ARDS, 136 (12%) developed AKI first, 303 (27%) ARDS first, and 697 (61%) had simultaneous diseases. Patients who developed ARDS after AKI had significantly increased ICU (29.4%) and hospital (36.8%) mortality compared to patients who developed AKI after ARDS (13.9% ICU mortality, 21.5% hospital mortality) (p < 0.001). Conclusions The combination of AKI and ARDS leads to worse outcomes, including longer hospital and ICU lengths of stay, higher mortality, longer kidney replacement therapy, and longer ventilation requirements than in patients with AKI or ARDS alone. Among patients with both diagnoses, those who developed ARDS after AKI had the highest mortality. Graphical abstract

28 November 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
XLXinyan Liu
Xinyan Liu
DYDapeng Yu
Dapeng Yu
TLTiantian Li
Tiantian Li
KZKehan Zhu
Kehan Zhu
YBYang Bi
Yang Bi
XSXuan Song
Xuan Song
Immune disorders caused by sepsis have recently drawn much attention. We sought to dynamically monitor the expression of small extracellular vesicle (sEV) miRNAs in peripheral blood during sepsis to explore these miRNAs as potential biomarkers for monitoring immune function in sepsis patients. This study included patients with sepsis. Blood samples were obtained from 10 patients on the first through 10th days, the 12th day and the 14th day since sepsis onset, resulting in 120 collected samples. Serum sEVs were extracted from peripheral venous blood, and levels of MIR497HG, miR‐195, miR‐497, and PD‐L1 in serum sEVs were detected by qPCR, and clinical information was recorded. Our study revealed that the levels of MIR497HG, miR‐195, miR‐497 and PD‐L1 in serum sEVs showed periodic changes; the time from peak to trough was approximately 4–5 days. The levels of sEV MIR497HG and miR‐195 had a positive linear relationship with SOFA score (r values were −0.181 and −0.189; p values were 0.048 and 0.039, respectively). The recorded quantities of sEV MIR497HG, miR‐195 and PD‐L1 showed a substantial correlation with ARDS. ROC curve analysis revealed that sEV MIR497HG, miR‐195 and miR‐497 could predict the 28‐day mortality of sepsis patients with an AUC of 0.66, 0.68 and 0.72, respectively. Levels of sEVs MIR497HG, miR‐195, miR‐497 and PD‐L1 showed periodic changes with the immune status of sepsis, which provides a new exploration direction for immune function biomarkers and immunotherapy timing in sepsis patients.

31 October 2023 in Libyan Journal of Medicine
Verified
Journal Article
Open access
LMLingyang Meng
Lingyang Meng
CWChaofan Wang
Chaofan Wang
XLXinyan Liu
Xinyan Liu
YBYang Bi
Yang Bi
KZKehan Zhu
Kehan Zhu
XSXuan Song
Xuan Song
Introduction: Temperature management is an important aspect of the treatment of critically ill patients, but there are differences in the measurement and management of temperature in different Intensive Care Units (ICUs). The objective of this study was to understand the current situation of temperature measurement and management in ICUs in China, and to provide a basis for standardized temperature management in ICUs.Methods: A 20-question survey was used to gather information on temperature management strategies from ICUs across China. Data such as method and frequency of temperature measurement, management goals, cooling measures, and temperature management recommendations were collected.Results: A total of 425 questionnaires from unique ICUs were included in the study, with responses collected from all provinces and autonomous regions in China. Mercury thermometers were the most widely used measurement tool (82.39%) and the axilla was the most common measurement site (96.47%). There was considerable variability in the frequency of temperature measurement, the temperature at which intervention should begin, intervention duration, and temperature management goals. While there was no clearly preferred drug-based cooling method, the most widely used equipment-based cooling method was the ice blanket machine (93.18%). The most frequent recommendations for promoting temperature management were continuous monitoring and targeted management.Conclusion: Our investigation revealed a high level of variability in the methods of temperature measurement and management among ICUs in China. Since fever is a common clinical symptom in critically ill patients and can lead to prolonged ICU stays, we propose that standardized guidelines are urgently needed for the management of body temperature (BT) in these patients.